KR910015298A - 오메프라졸 직장투여조성물 - Google Patents

오메프라졸 직장투여조성물 Download PDF

Info

Publication number
KR910015298A
KR910015298A KR1019900002526A KR900002526A KR910015298A KR 910015298 A KR910015298 A KR 910015298A KR 1019900002526 A KR1019900002526 A KR 1019900002526A KR 900002526 A KR900002526 A KR 900002526A KR 910015298 A KR910015298 A KR 910015298A
Authority
KR
South Korea
Prior art keywords
omeprazole
soluble
water
composition according
rectal
Prior art date
Application number
KR1019900002526A
Other languages
English (en)
Other versions
KR930000861B1 (ko
Inventor
김광식
Original Assignee
임성기
한미약품공업 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임성기, 한미약품공업 주식회사 filed Critical 임성기
Priority to KR1019900002526A priority Critical patent/KR930000861B1/ko
Priority to ES91102856T priority patent/ES2057628T3/es
Priority to CA002037101A priority patent/CA2037101C/en
Priority to DE69102307T priority patent/DE69102307T2/de
Priority to EP91102856A priority patent/EP0444625B1/en
Priority to US07/661,652 priority patent/US5219870A/en
Priority to JP3119605A priority patent/JPH0751503B2/ja
Publication of KR910015298A publication Critical patent/KR910015298A/ko
Application granted granted Critical
Publication of KR930000861B1 publication Critical patent/KR930000861B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

오메프라졸 직장투여조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본발명에 있어서의 조성물에 사용되는 방출화제의 사용량에 따른 시간별 방출률을 나타낸 그래프이다.

Claims (9)

  1. 오메프라졸을 유효성분으로 함유하는 조성물에 있어서, 기제로서 수용성 또는 유용성 기제를 함유하고 있으며, 안정화제로서는 수용성 염기성아미노산을 함유하고 있는 것을 특징으로 하는 오메프라졸 직장투여조성물.
  2. 제1항에 있어서, 상기 수용성기제로서는 폴리에틸렌 글리콜조합이 함유되어 있는 것을 특징으로 하는 오메프라졸 직장투여조성물.
  3. 제1항에 있어서, 상기 유용성개제로서는 아뎁스솔리두스가 함유되어 있는 것을 특징으로 하는 오메프라졸 직장투여조성물.
  4. 제1항에 또는 제3항에 있어서, 상기 유용성 기제가 함유되어 있는 경우에는 방출화제로서 소디움라우릴설페이트를 함유하고 있는 것을 특징으로 하는 오메프라졸 직장투여조성물.
  5. 제4항에 있어서, 상기 방출화제는 조성물의 전체량에 대하여 0.05 내지 1.0중량% 범위로 함유되어 있는 것을 특징으로 하는 오메프라졸 직장투여조성물.
  6. 제1항에 있어서, 상기 수용성 염기성아미노산은 아르기닌, 리진 또는 히스티딘인 것을 특징으로 하는 오메프라졸 직장투여조성물.
  7. 제1항 또는 제6항에 있어서 상기 수용성염기성아미노산은 상기 오메프라졸 1몰에 대해 0.1 내지 20몰로 함유되어 있는 것을 특징으로 하는 오메프라졸 직장투여조성물.
  8. 오메프라졸을 유효성분으로 하는 조성물을 제조함에 있어서, 수용성 또는 유용성 기제를 70∼80℃로 냉각시킨 다음, 여기에다 안정화제로서의 수용성 염기성아미노산과 유효성분인 오메프라졸을 첨가하여 혼합시켜서, 이를 필름에 충진, 냉각시킴을 특징으로 하는 오메프라졸 직장투여조성물.
  9. 제8항에 있어서, 상기 수용성 염기성아미노산은 상기 오메프라졸 1몰에 대해 0.1 내지 20몰의 비율로 첨가하여서 됨을 특징으로 하는 오메프라졸 직장투여조성물의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019900002526A 1990-02-27 1990-02-27 오메프라졸 직장투여 조성물 KR930000861B1 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1019900002526A KR930000861B1 (ko) 1990-02-27 1990-02-27 오메프라졸 직장투여 조성물
ES91102856T ES2057628T3 (es) 1990-02-27 1991-02-26 Composiciones de omeprazol diseñadas para administracion rectal y su proceso de preparacion.
CA002037101A CA2037101C (en) 1990-02-27 1991-02-26 Omeprazole compositions designed for administration in rectum
DE69102307T DE69102307T2 (de) 1990-02-27 1991-02-26 Omeprazolezusammensetzung zur rektalen Anwendung.
EP91102856A EP0444625B1 (en) 1990-02-27 1991-02-26 Omeprazole compositions designed for administration in Rectum
US07/661,652 US5219870A (en) 1990-02-27 1991-02-27 Omeprazole compositions designed for administration in rectum
JP3119605A JPH0751503B2 (ja) 1990-02-27 1991-02-27 オメプラゾールの直腸投与組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019900002526A KR930000861B1 (ko) 1990-02-27 1990-02-27 오메프라졸 직장투여 조성물

Publications (2)

Publication Number Publication Date
KR910015298A true KR910015298A (ko) 1991-09-30
KR930000861B1 KR930000861B1 (ko) 1993-02-08

Family

ID=19296479

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900002526A KR930000861B1 (ko) 1990-02-27 1990-02-27 오메프라졸 직장투여 조성물

Country Status (7)

Country Link
US (1) US5219870A (ko)
EP (1) EP0444625B1 (ko)
JP (1) JPH0751503B2 (ko)
KR (1) KR930000861B1 (ko)
CA (1) CA2037101C (ko)
DE (1) DE69102307T2 (ko)
ES (1) ES2057628T3 (ko)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
ZA982155B (en) * 1997-03-13 1998-12-01 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6602522B1 (en) * 1997-11-14 2003-08-05 Andrx Pharmaceuticals L.L.C. Pharmaceutical formulation for acid-labile compounds
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CA2310585C (en) * 1997-12-08 2005-08-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel administration form comprising an acid-labile active compound
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
FR2784897B1 (fr) * 1998-10-27 2002-11-29 Agronomique Inst Nat Rech Utilisation d'un laxatif osmotique non fermente dans le traitement et la prevention des cancers colorectaux
FR2784896B1 (fr) * 1998-10-27 2003-01-03 Agronomique Inst Nat Rech Utilisation du polyethylene-glycol dans le traitement et la prevention des cancers colorectaux
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
EP1469839A2 (en) * 2002-01-25 2004-10-27 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005007117A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN1813729A (zh) * 2005-02-02 2006-08-09 兰贝克赛实验室有限公司 苯并咪唑化合物的注射制剂
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0917675A2 (pt) * 2008-08-15 2015-12-01 Boehringer Ingelheim Int compostos orgânicos para cura de ferida
MX2011002558A (es) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009035019A1 (de) * 2009-07-28 2011-02-10 Leica Biosystems Nussloch Gmbh Histologisches Einbettmedium
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
EP2338477A1 (en) 2009-12-15 2011-06-29 bene-Arzneimittel GmbH Suppository comprising pantoprazole
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012171540A1 (en) 2011-06-15 2012-12-20 Bene-Arzneimittel Gmbh Suppository comprising pantoprazole comprised in pellets with a cellulose core
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
SE8500996D0 (sv) * 1985-03-01 1985-03-01 Haessle Ab Method of treatment
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
GB2214809A (en) * 1988-02-16 1989-09-13 American Cyanamid Co Non-steroidal anti-inflammatory suppositories

Also Published As

Publication number Publication date
CA2037101A1 (en) 1991-08-28
DE69102307T2 (de) 1995-02-09
KR930000861B1 (ko) 1993-02-08
DE69102307D1 (de) 1994-07-14
EP0444625B1 (en) 1994-06-08
CA2037101C (en) 1997-03-18
JPH04234817A (ja) 1992-08-24
EP0444625A1 (en) 1991-09-04
ES2057628T3 (es) 1994-10-16
JPH0751503B2 (ja) 1995-06-05
US5219870A (en) 1993-06-15

Similar Documents

Publication Publication Date Title
KR910015298A (ko) 오메프라졸 직장투여조성물
FI951266A (fi) Pieneliöitä tappavat detergentti-jodi-koostumukset, joilla on alentunut detergenttipitoisuus
SE8303531D0 (sv) Farmaceutisk komposition
BR9611306A (pt) Preparação farmacêutica e, composto farmacêutica estável.
SE8300736D0 (sv) Novel pharmacologically active compounds
DE3581819D1 (de) Pyridazinamine wirksam gegen viren.
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
IT1282686B1 (it) Composti in grado di ridurre la tossicita' da farmaci
LV10954A (lv) Benzimidazola atvasinajumi to iegusanas panemiens un tos saturosa farmaceitiska kompozicija
ES8303092A1 (es) Procedimiento para la obtencion de lapices antimicoticos con mayor liberacion de sustancia activa.
EA199900876A1 (ru) Фармацевтические композиции против кашля
DK0658596T3 (da) Sammensætning på basis af biopolymerer med hurtig hydratisering
SE8600658D0 (sv) Novel composition of matter
KR930001903A (ko) 유비데카레논 경구용 수용액 제제
FI962056A0 (fi) Uusi farmaseuttinen koostumus stabiilin jauheen valmistamiseksi, joka sisältää asetyylisalisyylihapon ja metoklopramidin yhdistelmän käsittävän aktiivisen aineosan
CA1269322C (en) COMPOUNDS CONTAINING CITRONELLYL NITRILE AND CITRONELLOL TO REPELLENT ANIMALS
TR199902733T2 (xx) Tizoksanit ve nitazoksanitten olu�an farmas�tik kompozisyonlar.
DK78487A (da) Farmaceutisk praeparat indeholdende et i vand kvaeldende polymermateriale
JPS5750914A (en) Betamethasone external pharmaceutical
SE8001425L (sv) Cytostatiskt verkande lekemedel resp farmaceutiska beredningar
AR246157A1 (es) Composicion plaguicida y procedimiento para prepararla.
KR900016156A (ko) 퀴녹살린 유도체 및 궤양치료제
ES521433A0 (es) Un procedimiento para la preparacion de una composicion de oxido de amina.
KR940008695A (ko) 안티트롬빈 iii제제
ES2059387T3 (es) Concentrado de estabilizante mejorado.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E801 Decision on dismissal of amendment
G160 Decision to publish patent application
O035 Opposition [patent]: request for opposition
E701 Decision to grant or registration of patent right
O073 Decision to grant registration after opposition [patent]: decision to grant registration
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20091223

Year of fee payment: 18

EXPY Expiration of term